Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2202-2210

  Welsh, Paul ^a   Woodward, Mark ^b   Hillis, Graham S ^b   Li, Qiang ^b   Marre, Michel ^c   Williams, Bryan ^d   Poulter, Neil ^e   Ryan, Louise ^f   Harrap, Stephen ^g   Patel, Ansuhka ^b   Chalmers, John ^b   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BICHAT HOSPITAL   (France)

^d The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY TROPONIN T; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO; TRIACYLGLYCEROL; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CASE STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PREDICTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTING HEART RATE; RETINOPATHY; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD; CASE CONTROL STUDY; COMPLICATION; KIDNEY DISEASES; MIDDLE AGED; PROGNOSIS; RISK FACTOR;

BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TROPONIN;

EID: 84904966103     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2625     Document Type: Article

References (35)

1. Wannamethee SG, Welsh P, Lowe G.D., et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011; 58: 56-64
2. Welsh P, Doolin O, Willeit P., et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J 2013; 34: 443-450
3. Wang TJ, Wollert KC, Larson M.G., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596-1604
4. Hillis GS, Welsh P, Chalmers J., et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care 2014; 37: 295-303
5. Collins AJ, Foley RN, Herzog C, et al US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011; 57(Suppl. 1): A8, e1-e526
6. Elsayed EF, Tighiouart H, Griffith J., et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167: 1130-1136
7. Tanaka S, Tanaka S, Iimuro S., et al.; Japan Diabetes Complications Study Group; Japanese Elderly Diabetes Intervention Trial Group. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 2013; 36: 1193-1199
8. Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care 2011; 34(Suppl. 2): S145-S149
9. Rosenson RS, Fioretto P, Dodson PM Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 2011; 218: 13-18
10. Rossetti E, Mariani M, Poli A, et al. NT pro-Btype natriuretic peptide levels are related to microvascular reperfusion in patients undergoing direct percutaneous transluminal coronary angioplasty for anterior ST-segment elevation myocardial infarction. J Cardiovasc Med (Hagerstown) 2010; 11: 359-364
11. Grauslund J, Nybo M, Green A., Sjølie AK. N-terminal pro brain natriuretic peptide reflects long-term complications in type 1 diabetes. Scand J Clin Lab Invest 2010; 70: 392-398
12. Hillis GS, Hata J, Woodward M., et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetesmellitus. J Am Heart Assoc 2012; 1: e002832
13. Boertien WE, Riphagen IJ, Drion I, et al Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 2013; 56: 1680-1688
14. Woodward M. Epidemiology: Study Design and Data Analysis. Boca Raton, Florida, Chapman & Hall/CRC, 2004
15. Patel A, MacMahon S, Chalmers J., et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
16. Patel A, MacMahon S, Chalmers J., et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
17. Giannitsis E, Kurz K, Hallermayer K., Jarausch J, Jaffe AS, Katus HA Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 254-261
18. Newson RB. Comparing the predictive power of survival models using Harrells c or Somers' D. Stata J 2011; 10: 339-358
19. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21
20. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J 2012; 33: 2771-2782b
21. Lanza GA, Crea F. Primary coronary micro-vascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 2010; 121: 2317-2325
22. Hallén J., Jensen JK, Buser P, Jaffe A.S., Atar D. Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction. Acute Card Care 2011; 13: 48-51
23. Mayr A, Klug G, Schocke M., et al. Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers. Int J Cardiol 2012; 157: 391-396
24. Wu AH, Jaffe AS, Apple F.S., et al.; NACB Writing Group; NACB Committee. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: useofcardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007; 53: 2086-2096
25. Zoungas S, de Galan BE, Ninomiya T, et al.; ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074
26. Ismail-Beigi F., Craven TE, O'Connor PJ, et al.; ACCORD Study Group. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 2012; 81: 586-594
27. Duckworth WC, Abraira C, Moritz T.E., et al.; Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications 2011; 25: 355-361
28. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169
29. Preiss D, Sattar N, McMurray JJ A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 2011; 161: 210-219, e1
30. Bonomini M, Sirolli V, Magni F., Urbani A. Proteomics and nephrology. J Nephrol 2012; 25: 865-871
31. Alkhalaf A, Zürbig P, Bakker S.J., et al.; PREDICTIONS Group. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE 2010; 5: e13421
32. Hellemons ME, Lambers Heerspink HJ, Gansevoort RT, de Zeeuw D, Bakker SJ. Highsensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes. J Hypertens 2013; 31: 805-812
33. Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol 2010; 55: 340-347
34. Agarwal SK, Avery CL, Ballantyne C.M., et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem 2011; 57: 891-897
35. Cauliez B, Guignery J, Marinier S., Mariau I, Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem 2008; 45: 318-319